Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
ESSA Pharma ( (EPIX) ) just unveiled an update.
On September 10, 2025, ESSA Pharma Inc. announced the adjournment of its special meeting, initially scheduled for the same day, to September 29, 2025. The meeting aims to discuss and approve a transaction where XenoTherapeutics, a non-profit biotechnology company, will acquire all of ESSA’s outstanding common shares. The adjournment is intended to allow further discussions on the financial terms of the transaction, including cash forecasts and distribution to shareholders. The rescheduling of the meeting and the British Columbia Supreme Court hearing reflects ESSA’s ongoing negotiations to potentially revise the transaction’s financial terms, impacting the company’s future operations and stakeholder interests.
The most recent analyst rating on (EPIX) stock is a Hold with a $2.25 price target. To see the full list of analyst forecasts on ESSA Pharma stock, see the EPIX Stock Forecast page.
Spark’s Take on EPIX Stock
According to Spark, TipRanks’ AI Analyst, EPIX is a Neutral.
ESSA Pharma’s overall score reflects significant financial challenges with no revenue and ongoing losses. Technical indicators provide some positive signals, but caution is advised due to potential overbought conditions. The negative P/E ratio and lack of dividends further underline investment risks.
To see Spark’s full report on EPIX stock, click here.
More about ESSA Pharma
ESSA Pharma Inc. is a pharmaceutical company that was previously focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer.
Average Trading Volume: 5,857,436
Technical Sentiment Signal: Hold
Current Market Cap: $11.21M
For a thorough assessment of EPIX stock, go to TipRanks’ Stock Analysis page.